Possible Case: Heparin
Overdosing in Infants
Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
SOUTH EASTON, Mass., December 01, 2008 /PRNewswire-FirstCall/ — Pressure BioSciences, Inc. (”PBI” or the “Company”) today announced a comprehensive restructuring program designed to significantly reduce costs, centralize core operations, and…
TargetRx’s LaunchAdvantage Offers Critical Insight for Successful Drug Introductions
First in Company’s New Suite of Products Leverages Four Forces of Prescribing to Close the Gap Between Intent to Prescribe and Actual NRx
HORSHAM, Pa.–(BUSINESS WIRE)–Dec 1, 2008 - With the impending “patent cliff,” it is more critical…
Settlement: Bayer
Reaches $97.5 Million Settlement with Department of Justice
$15K, drugs confiscated from suspected dealer’s bank deposit box
Authorities seized more than $10,000 cash and 1,003 roxicodone pills from a bank safe deposit box on Tuesday.
Johnson & Johnson Announces Definitive Agreement to Acquire Mentor Corporation
NEW BRUNSWICK, N.J. and SANTA BARBARA, Calif., December 01, 2008 /PRNewswire-FirstCall/ — Johnson & Johnson and Mentor Corporation , a leading supplier of medical products for the global aesthetic market, today announced a definitive agreement…
Hemispherx Biopharma Introduces Expense Reduction Program
Medical, Regulatory, Manufacturing Operations Remain Intact
Philadelphia, PA, Friday, November 28, 2008: Hemispherx Biopharma, Inc. (AMEX, HEB) announced today a series of steps to reduce expenses.
As Hemispherx Biopharma continues to strive to…
Arpida to Restructure and Focus on Key Projects
REINACH, Switzerland, November 27, 2008 /PRNewswire-FirstCall/ — Arpida announced today that it is refocusing all projects and priorities around the key strategic asset Iclaprim. The company says this is to be seen as a consequence of the negative…
Quintiles Acquires Targeted Molecular Diagnostics
Acquisition to Enhance Quintiles’ Oncology Drug Development Services
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Dec 1, 2008 - Quintiles Transnational Corp. today announced that it has acquired Targeted Molecular Diagnostics (TMD) of Westmont,…
Introgen Restructures Operations to Focus on Revenue-Generating Manufacturing Capabilities
Chief Executive Officer, Other Senior Executive Officers, Resign in Connection with Cost Cutting Move
AUSTIN, Texas–(BUSINESS WIRE)–Nov 26, 2008 - Introgen Therapeutics, Inc. (NASDAQ:INGN), today announced that it has strategically reorganized the…